Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.44 |
| ▸ | HTR2A | P28223 | 5/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10446436 | 0.89 | CYP1A2 (0.47) | CYP1A2TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL18543623 | 0.85 | CYP1A2 (0.51) | CYP1A2TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL27828878 | 0.79 | ALDH1A1 (0.34) | — | |
| SCHEMBL25368352 | 0.78 | MAPT (0.42) | — | |
| SCHEMBL3932880 | 0.78 | MEP1B (0.35) | CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL27828906 | 0.78 | POLB (0.49) | — | |
| SCHEMBL27668305 | 0.77 | MEP1B (0.47) | CYP1A2TAAR1HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL27730362 | 0.76 | MEP1B (0.46) | CYP1A2TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL24935139 | 0.76 | CYP19A1 (0.37) | CYP1A2TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL6284487 | 0.74 | TAAR1 (0.44) | TAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8835440-B2 | Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-20130324517-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-05 | — | — | US | disclosed |
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2001040193-A1 | METHOD FOR THE SYNTHESIS OF PYRAZOLINES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | CCR2, CCR1, CCR5 | CYP1A2 528/4885TAAR1 410/4885HTR2A 892/4885 |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | CCR2, CCR5, CCR1 | CYP1A2 386/4885TAAR1 223/4885HTR2A 474/4885 |
| US-20130324517-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | CCR2, CCR5, CCR1 | CYP1A2 748/4885TAAR1 505/4885HTR2A 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.